Needham & Company LLC restated their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP - Free Report) in a research note released on Tuesday morning,Benzinga reports. Needham & Company LLC currently has a $81.00 price target on the stock.
A number of other equities research analysts also recently weighed in on the company. Chardan Capital reaffirmed a "buy" rating and set a $82.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, June 26th. HC Wainwright reissued a "buy" rating and issued a $65.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, June 27th. The Goldman Sachs Group cut their price objective on CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. JMP Securities reissued a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Finally, Piper Sandler reissued an "overweight" rating and issued a $105.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Two analysts have rated the stock with a sell rating, six have given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, CRISPR Therapeutics has a consensus rating of "Hold" and an average price target of $71.75.
Read Our Latest Research Report on CRISPR Therapeutics
CRISPR Therapeutics Stock Down 3.7%
Shares of CRSP traded down $2.20 during midday trading on Tuesday, reaching $56.80. 2,883,963 shares of the stock were exchanged, compared to its average volume of 1,945,293. CRISPR Therapeutics has a 12-month low of $30.04 and a 12-month high of $63.68. The firm has a 50 day simple moving average of $42.52 and a 200-day simple moving average of $41.28. The company has a market cap of $4.91 billion, a price-to-earnings ratio of -12.57 and a beta of 1.82.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. During the same period in the previous year, the company earned ($1.43) EPS. The business's revenue for the quarter was up 71.6% compared to the same quarter last year. Research analysts expect that CRISPR Therapeutics will post -5.16 earnings per share for the current fiscal year.
Insider Transactions at CRISPR Therapeutics
In other CRISPR Therapeutics news, insider Naimish Patel sold 3,932 shares of the firm's stock in a transaction that occurred on Thursday, May 29th. The stock was sold at an average price of $35.94, for a total value of $141,316.08. Following the sale, the insider owned 6,068 shares of the company's stock, valued at $218,083.92. This trade represents a 39.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 4.30% of the stock is owned by company insiders.
Institutional Trading of CRISPR Therapeutics
Institutional investors have recently modified their holdings of the company. Magnetar Financial LLC acquired a new stake in shares of CRISPR Therapeutics during the 4th quarter worth approximately $359,000. Baker BROS. Advisors LP grew its holdings in shares of CRISPR Therapeutics by 55.1% during the 4th quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company's stock worth $51,483,000 after purchasing an additional 464,936 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of CRISPR Therapeutics by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company's stock worth $68,329,000 after purchasing an additional 10,579 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in shares of CRISPR Therapeutics by 14.3% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 39,189 shares of the company's stock worth $1,334,000 after purchasing an additional 4,914 shares in the last quarter. Finally, Green Alpha Advisors LLC grew its holdings in shares of CRISPR Therapeutics by 132.9% during the 1st quarter. Green Alpha Advisors LLC now owns 57,361 shares of the company's stock worth $1,952,000 after purchasing an additional 32,732 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.
About CRISPR Therapeutics
(
Get Free Report)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Recommended Stories
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
